Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (February 2026)
17 slides from Aim Immunotech's investor presentation, Feb 5, 2026
Slide 1: Ampligen Breakthroughs in Treating Late-Stage Pancreatic Cancer
NYSE American: AIM ImmunoTech = Al M | aimimmuno.com <7) Ampligen Breakthroughs in Treating Late-Stage Pancreatic Cancer Corporate Presentation - February 2026
Slide 2: Forward-Looking Statements
eS efits atements” = e Forward-Looking St om ‘Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements conta
Slide 3: Late-stage clinical immuno-pharma company
SS AIM ImmunoTech We are a late-stage clinical immuno-pharma company focused on developing therapeutics across a number of disease areas, from immuno-oncology to immune disorders to viral diseases
Slide 4: Unlocking the value of Ampligen with the priority goal of new drug approval in pancreatic cancer
Unlocking the value of Ampligen with the priority goal of new drug approval in pancreatic cancer Unmet medical needs with little-to-no pipeline competition Consistent positive data from open-label, late-stage cancer clinical programs World-class cancer research centers Big Pharma collaborators, incl
Slide 5: Ampligen is a Toll-like receptor agonist
Ampligen is a Toll-like receptor 3 agonist shown in animal and human studies to reprogram the tumor microenvironment, promote immune-mediated tumor destruction, and potentially convert “cold” tumors into “hot” tumors, enhancing responsiveness to checkpoint inhibitors and activating innate immune res
Slide 6: Ensuring Effective Chemokine Modulation in Tumors is Important for Teff Cell Infiltration and Increased Survival
Ensuring Effective Chemokine Modulation in Tumors is Important for Teff Cell Infiltration and Increased Survival Ampligen shown in clinical trials to increase CXCL10 and decrease CCL22 intratumorally with associated increase in the Teff/Treg ratio in subjects This helps explain Ampligen’s broad-spec
Slide 7: Unique TLR3 agonist with differentiated mechanism and favorable safety profile
Unique TLR3 agonist with differentiated mechanism and favorable safety profile Activates TRIF pathway, avoiding the systemic inflammatory MyD88 pathway IV administration over 30-60 minutes Well tolerated across >100,000 IV doses and in Phase 1 IP and IN studies Extensive clinical exposure (>600 pati
Slide 8: Late-stage metastatic pancreatic cancer is a primary focus for Ampligen's development
Late-stage metastatic pancreatic cancer is a primary focus for Ampligen’s development given... * The lethal malignancy’s high unmet need * The large potential market + AIM’s U.S. patent for Ampligen in combination with PD-L1 drugs for the treatment of cancers, including pancreatic cancer + AIM’s gra
Slide 9: Pancreatic Cancer Intellectual Property Portfolio
Pancreatic Cancer Intellectual Property Portfolio Patent protection regarding pancreatic cancer and oncology development ¢ United States - Methods involve the administration of a unique synergistic combination of Ampligen and an anti-PD-L1 in the treatment of pancreatic cancer, renal cell carcinoma,
Slide 10: Foundation for Success in Pancreatic Cancer
Foundation for Success in Pancreatic Cancer Netherlands government-approved Early Access Program (EAP) Indicated Statistically Significant Increased Overall Survival Compared to Historical Controls in the Treatment of Late-Stage Pancreatic Cancer Cts Erasmus University Medical Center Survival Data:
Slide 11: EAP - A well-matched historical control group was used to compare outcomes
EAP - Awell-matched historical control group (established by the below p-values) was used to compare outcomes in the single-arm study 09 645 28.4 64.648. : eee FOLFIRINOX cycles, qya3 aan oa08 Mean (3) 743: a ; iy Male (n, 18, 67% 36, 63% ale 9, 33% 21, 37% aca b u Locally Advanced Pancreatic 5, 19%
Slide 12: Ampligen demonstrated significant improvement in OS and PFS as compared with historical controls
Ampligen demonstrated significant improvement in OS and PFS as compared with historical controls Progression-Free Survival (PFS) Overall Survival (OS) + Ampligen n=57 1007 + Ampligen n=57 + Control n=27 s + Control n=27 7 rg z £ g zg FS B 504 B 50 RS SS 7 Months From Pee Start Months From FOLFIRINOX
Slide 13: Baseline Neutrophil/Lymphocyte (N/L) ratio appear to be predictive of Ampligen response
Baseline Neutrophil/Lymphocyte (N/L) ratio appear to be predictive of Ampligen response Overall Survival (OS) Progression-Free Survival (PFS) 1004 ~~ NIL < 4.5 (n=39) 1004 ~ NIL < 4.5 (n=39) + NIL > 4.5 (n=9) + NIL > 4.5 (n=9) 3 + Control (n=27) s + Control (n=27) s FS = G 504 B 504 x x 0. T T 1 0:
Slide 14: CA19-9 tumor marker levels appear to be predictive of Ampligen response
CA19-9 tumor marker levels appear to be predictive of Ampligen response Progression-Free Survival (PFS) 1004 + CA19-9 <1000 (n=49) “© CA19-9 >=1000 (n=8) ~ Control (n=27) § & B 504 PS 0. T T 1 0 20 40 60 Months From FOLFIRINOX Start Pioganimate con) $0001 ca19-9<1000 HR ogrank «39 (.22--71) vs. Cont
Slide 15: DURIPANC study: Sponsor Erasmus University Medical Center
o4 io yy) i; Sponsor: Erasmus University Medical Center Collaborators: AIM ImmunoTech and AstraZeneca Study Title: Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod (Ampligen) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
Slide 16: DURIPANC mid-year 2025 update and current status
The mid-year 2025 update reported that among the 14 patients evaluable for progression-free survival, eight patients experienced disease progression within six months of treatment initiation and three patients had a progression-free survival duration of more than six months. Of the 11 patients evalu
Slide 17: Proven Management Team
Proven Management Team Peter W. Rodino III, JD Chief Operating Officer, Executive Director for Governmental Relations, General Counsel, Secretary William Mitchell, MD, PhD Chairman of the Board of Directors Christopher Nicodemus, MD Science Officer
AIM ImmunoTech — Investor Presentation (February 2026) on 6ix